Chunyan L. Li

Wuhan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Intratumoral PD-1-directed IL-2 expression via oncolytic vaccinia virus elicits superior antitumor effects with enhanced safety.

Intratumoral PD-1-directed IL-2 expression via oncolytic vaccinia virus elicits superior antitumor effects with enhanced safety.

Journal: Journal for immunotherapy of cancer

Published: February 23, 2026

Non-Secreted Mature Decoy-Resistant IL-18-Armed Oncolytic Vaccinia Virus Elicits Potent Antitumor Effects in an Aggressive Murine Ovarian Cancer Model.

Non-Secreted Mature Decoy-Resistant IL-18-Armed Oncolytic Vaccinia Virus Elicits Potent Antitumor Effects in an Aggressive Murine Ovarian Cancer Model.

Journal: Cancers

Published: February 14, 2026

Novel progress in exploring drug resistance mechanisms of breast cancer by single-cell sequencing technology

Novel progress in exploring drug resistance mechanisms of breast cancer by single-cell sequencing technology

Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology

Published: December 08, 2025

IGF2BP3 Modulates mRNA Splicing and Stability to Promote Trophoblast Progression via Interaction with PDE3A and Suppression by miR-196a-5p in Preeclampsia.

IGF2BP3 Modulates mRNA Splicing and Stability to Promote Trophoblast Progression via Interaction with PDE3A and Suppression by miR-196a-5p in Preeclampsia.

Journal: Biomedicines

Published: April 14, 2025

Scutellarin Alleviates CCl4-Induced Liver Fibrosis by Regulating Intestinal Flora and PI3K/AKT Signaling Axis.

Scutellarin Alleviates CCl4-Induced Liver Fibrosis by Regulating Intestinal Flora and PI3K/AKT Signaling Axis.

Journal: International journal of molecular sciences

Published: February 18, 2025

Oncolytic vaccinia virus expressing non-secreted decoy-resistant IL-18 mutein elicits potent antitumor effects with enhanced safety.

Oncolytic vaccinia virus expressing non-secreted decoy-resistant IL-18 mutein elicits potent antitumor effects with enhanced safety.

Journal: Molecular therapy. Oncology

Published: January 21, 2025

Efficacy and safety of angiogenesis inhibitors combined with poly ADP ribose polymerase inhibitors in the maintenance treatment of advanced ovarian cancer: a meta-analysis.

Efficacy and safety of angiogenesis inhibitors combined with poly ADP ribose polymerase inhibitors in the maintenance treatment of advanced ovarian cancer: a meta-analysis.

Journal: Frontiers in oncology

Published: August 07, 2024

Efficacy and safety of first-line immunotherapy-containing regimens compared with chemotherapy for advanced or metastatic urothelial carcinoma: a network meta-analysis of randomized controlled trials.

Efficacy and safety of first-line immunotherapy-containing regimens compared with chemotherapy for advanced or metastatic urothelial carcinoma: a network meta-analysis of randomized controlled trials.

Journal: Frontiers in oncology

Published: June 23, 2024

Comparative complications of prepectoral versus subpectoral breast reconstruction in patients with breast cancer: a meta-analysis.

Comparative complications of prepectoral versus subpectoral breast reconstruction in patients with breast cancer: a meta-analysis.

Journal: Frontiers in oncology

Published: May 27, 2024

Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis.

Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis.

Journal: Frontiers in immunology

Published: May 10, 2024

Efficacy and safety of PD-1/L1 inhibitors as first-line therapy for metastatic colorectal cancer: a meta-analysis.

Efficacy and safety of PD-1/L1 inhibitors as first-line therapy for metastatic colorectal cancer: a meta-analysis.

Journal: Frontiers in immunology

Published: April 30, 2024

Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, her2-negative breast cancer: a network meta-analysis.

Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, her2-negative breast cancer: a network meta-analysis.

Journal: Frontiers in immunology

Published: April 19, 2024

Showing 1-12 of 33

Last Updated: 09/26/2026